MedTrace Logo

A Phase I Study of Vitargus® in Vitrectomy

NCT04481386 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2020-09-09

No results posted yet for this study

Summary

A Phase I, safety and tolerability study of Vitargus® in vitrectomy surgery

Conditions

  • Vitreo-retinal Surgery

Interventions

DEVICE

Vitargus, BFC-1401

A single intravitreal (IVT) dose of BFC-1401 in participants as a vitreous substitute during vitrectomy surgery.

Sponsors & Collaborators

  • BioFirst Corporation

    lead INDUSTRY

Principal Investigators

  • Andrew Chang, MD, Ph.D · Sydney Retina Clinic | Medical Director

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2018-07-02
Completion
2018-07-02

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04481386 on ClinicalTrials.gov